260 related articles for article (PubMed ID: 23232055)
1. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
Kasten BB; Liu T; Nedrow-Byers JR; Benny PD; Berkman CE
Bioorg Med Chem Lett; 2013 Jan; 23(2):565-8. PubMed ID: 23232055
[TBL] [Abstract][Full Text] [Related]
2. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
3. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
4. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
Nedrow-Byers JR; Moore AL; Ganguly T; Hopkins MR; Fulton MD; Benny PD; Berkman CE
Prostate; 2013 Mar; 73(4):355-62. PubMed ID: 22911263
[TBL] [Abstract][Full Text] [Related]
5. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
6. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
7. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
[TBL] [Abstract][Full Text] [Related]
8. A PSMA-targeted doxorubicin small-molecule drug conjugate.
Yoon H; Savoy EA; Mesbahi N; Hendricksen AT; March GL; Fulton MD; Backer BS; Berkman CE
Bioorg Med Chem Lett; 2024 May; 104():129712. PubMed ID: 38521177
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
[TBL] [Abstract][Full Text] [Related]
10. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
13. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
14. D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer.
Sarkis M; Minassian G; Mitri N; Rahme K; Fracasso G; El Hage R; Ghanem E
ACS Appl Bio Mater; 2023 Feb; 6(2):819-827. PubMed ID: 36755401
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
16. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Guo J; O'Driscoll CM; Holmes JD; Rahme K
Int J Pharm; 2016 Jul; 509(1-2):16-27. PubMed ID: 27188645
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA).
Hara D; Tao W; Totiger TM; Pourmand A; Dogan N; Ford JC; Shi J; Pollack A
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):220-232. PubMed ID: 33964351
[TBL] [Abstract][Full Text] [Related]
18. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Rahme K; Guo J; Holmes JD
Methods Mol Biol; 2019; 1974():291-301. PubMed ID: 31099011
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
[TBL] [Abstract][Full Text] [Related]
20. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
